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ARTICLE
An ErbB2/c-Src axis links bioenergetics with PRC2
translation to drive epigenetic reprogramming and
mammary tumorigenesis
Harvey W. Smith et al.#
Dysregulation of histone modiﬁcations promotes carcinogenesis by altering transcription.
Breast cancers frequently overexpress the histone methyltransferase EZH2, the catalytic
subunit of Polycomb Repressor Complex 2 (PRC2). However, the role of EZH2 in this setting
is unclear due to the context-dependent functions of PRC2 and the heterogeneity of breast
cancer. Moreover, the mechanisms underlying PRC2 overexpression in cancer are obscure.
Here, using multiple models of breast cancer driven by the oncogene ErbB2, we show that the
tyrosine kinase c-Src links energy sufﬁciency with PRC2 overexpression via control of mRNA
translation. By stimulating mitochondrial ATP production, c-Src suppresses energy stress,
permitting sustained activation of the mammalian/mechanistic target of rapamycin complex 1
(mTORC1), which increases the translation of mRNAs encoding the PRC2 subunits Ezh2 and
Suz12. We show that Ezh2 overexpression and activity are pivotal in ErbB2-mediated
mammary tumourigenesis. These results reveal the hitherto unknown c-Src/mTORC1/PRC2
axis, which is essential for ErbB2-driven carcinogenesis.
https://doi.org/10.1038/s41467-019-10681-4 OPEN
.Correspondence and requests for materials should be addressed to W.J.M. (email: william.muller@mcgill.ca). #A full list of authors and their afﬁliations
appears at the end of the paper.
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The lysine methyltransferase Enhancer of Zeste Homolog 2(EZH2) is the catalytic subunit of Polycomb RepressorComplex 2 (PRC2), which represses transcription via di-
and tri-methylation of histone H3 on lysine 27 (H3K27me2/3)1. A
key regulator of pluripotency and differentiation2,3, PRC2 also
has a complex role in cancer, with gain and loss-of-function
mutations in PRC2 components reﬂecting context-speciﬁc
oncogenic and tumor suppressive activities4. Some cancers also
overexpress PRC2 components4, increasing the likelihood that
PRC2 will bind chromatin at transiently repressed loci to enforce
stable transcriptional silencing4. Thus, under conditions where
PRC2 exerts oncogenic effects, its overexpression may facilitate
tumorigenesis in the absence of activating mutations of its
components. This is thought to be the case in breast cancer,
where EZH2 overexpression is associated with poor prognosis5.
However, there are conﬂicting reports as to whether EZH2
overexpression drives breast cancer growth and progression5 or is
merely correlative6,7. This is likely to reﬂect the heterogeneous
nature of breast cancer, which comprises a spectrum of subtypes
distinguished by pathological characteristics, gene expression
patterns and genomic events8. Approximately 15–20% of breast
cancers overexpress the receptor tyrosine kinase (RTK) ErbB2/
HER2, typically due to ERBB2 gene ampliﬁcation8,9, which leads
to aggressive disease with poor prognosis. Despite the fact that
ERBB2-positive (ERBB2+) tumors are among those with the
highest EZH2 expression and H3K27 tri-methlyation10, few stu-
dies have examined the functional requirement for
EZH2 speciﬁcally in ERBB2+ breast cancer. Crucially, the
molecular pathways promoting EZH2/PRC2 overexpression are
incompletely understood, despite their potential importance in
mediating epigenetic dysregulation and tumor progression in
these cancers.
Metabolic reprogramming fuels neoplastic growth by providing
energy and biosynthetic intermediates11 and is also linked to
epigenetic dysregulation12,13 since DNA and histone modifying
enzymes require metabolites as cofactors and co-substrates and
are thus regulated by pathways producing and consuming these
metabolites12,13. Metabolic pathways are reprogrammed in cancer
cells by genetic alterations in enzymes and their regulators and by
aberrant signaling following activation of canonical oncogenes
and inactivation of tumor suppressor genes11. Although research
in this area has focussed largely on up-regulation of aerobic
glycolysis (the Warburg Effect), cancer cells can also depend on
ATP synthesis through mitochondrial oxidative phosphorylation
(OXPHOS) to fulﬁll their bioenergetic requirements11. Given the
central role of these metabolic processes in carcinogenesis, further
study of their intersections with signaling and epigenetics is
warranted.
Here, we apply an integrative approach involving multiple
pre-clinical models and analysis of clinical samples to delineate
a pathway mediating the overexpression of key PRC2 subunits
in ERBB2+ breast cancer. Our results demonstrate a previously
unrecognized mechanism whereby the tyrosine kinase c-Src,
which is frequently hyper-activated in ERBB2+ breast cancer14,
enhances mitochondrial ATP synthesis to alleviate cellular
energy stress. This enables mTORC1 activation, elevating the
translation of mRNAs encoding Ezh2 and Suz12, a second
essential subunit of PRC2. We show that down-regulation of
Ezh2 expression or inhibition of its methyltransferase activity
severely impairs the growth of ErbB2+ tumor cells, while
inhibition or genetic ablation of Ezh2 in vivo ablates ErbB2-
driven mammary epithelial tumorigenesis. Collectively, these
observations show how oncogene-dependent bioenergetic
modulation, through reprogramming mRNA translation, drives
epigenetic alterations that are essential for ErbB2-driven breast
cancer.
Results
c-Src ablation impairs ErbB2-driven mammary tumorigenesis.
c-Src mediates signaling towards mitogenic and pro-invasive
pathways by ErbB2 and related RTKs15,16. However, the
requirement for c-Src in ErbB2-driven transformation in vivo is
unknown. To directly address this issue, we generated a unique
GEMM combining conditional Src gene targeting (c-SrcL/L)17
with mammary epithelial co-expression of oncogenic ErbB2 and
Cre recombinase18 (referred to as NIC; Supplementary Fig. 1a).
Ablation of one (c-Src+/L) or both (c-SrcL/L) Src alleles sig-
niﬁcantly delayed mammary tumorigenesis, with the most severe
phenotype in the latter (Fig. 1a). NIC/c-SrcL/L tumors were devoid
of c-Src protein (Supplementary Fig. 1b). While c-Src-deﬁcient
tumors remained multifocal, their growth was severely impaired
(Fig. 1b), correlating with signiﬁcantly reduced proliferation
(Ki67) and impaired cell cycle progression (BrdU) (Fig. 1c).
c-Src-deﬁcient tumors retained the solid adenocarcinoma
pathology typically associated with ErbB2-expressing GEMMs
but showed histological evidence of necrosis (Supplementary
Fig. 1c) and slightly increased apoptosis (TUNEL; Supplementary
Fig. 1d) as compared to their c-Src+/+ counterparts. Cells derived
from c-Src-deﬁcient tumors proliferated at a dramatically lower
rate than c-Src-proﬁcient cell lines in culture (Supplementary
Fig. 1e), suggesting that the effects of c-Src deletion on growth are
tumor cell-intrinsic. However, as Src family kinase (SFK) activity
has been associated with angiogenesis during development and in
cancer19,20, we examined the presence of CD31+ endothelial cells
in control and c-Src-deﬁcient tumors, ﬁnding no signiﬁcant dif-
ference (Supplementary Fig. 1f). Overall, these data show that
c-Src loss causes a tumor cell-intrinsic proliferation defect that
signiﬁcantly impairs ErbB2-driven mammary tumorigenesis.
c-Src enhances Ezh2 and Suz12 translation and PRC2 activity.
To gain mechanistic insight, we determined the effects of c-Src
ablation on steady-state mRNA levels in ErbB2-driven mammary
tumors using DNA microarrays, identifying 602 transcripts up-
regulated and 785 down-regulated in NIC/c-SrcL/L tumors com-
pared to NIC/c-Src+/+ controls. Bioinformatic analysis using two
independent databases (ChEA and ENCODE) revealed that genes
up-regulated in c-Src-deﬁcient tumors were signiﬁcantly enriched
in predicted targets of PRC2, which was the only factor identiﬁed
using both databases (Fig. 1d). In contrast, the same analyses
failed to identify candidate regulators of genes downregulated in
c-Src-deﬁcient tumors. KEGG (Kyoto Encyclopedia of Genes and
Genomes) and GO (Gene Ontology) analysis revealed that genes
up-regulated in c-Src-deﬁcient tumors were involved in adhesion
to the extracellular matrix (ECM), cell–cell contact and central
carbon metabolism (Supplementary Fig. 2a). While these analyses
found fewer pathways and functions among genes down-
regulated in NIC/c-SrcL/L tumors, they did identify down-
regulation of protein trafﬁcking pathways and functions typi-
cally associated with neurons (Supplementary Fig. 2b).
To conﬁrm our ﬁndings, we performed RNA-Seq on cell lines
derived from control and c-Src-deﬁcient ErbB2+ tumors and
identiﬁed candidate regulators of differentially expressed genes
using ChEA, ENCODE and ingenuity pathway analysis (IPA),
focussing on regulators identiﬁed by at least two methods in both
tumors and cell lines. Using these criteria, we identiﬁed two
PRC2 subunits (Ezh2 and Suz12) as candidate regulators of genes
up-regulated following c-Src loss (Supplementary Fig. 2c).
Accordingly, a signiﬁcant reduction in H3K27me3 was observed
upon c-Src ablation (Fig. 1e), which was conﬁrmed by chromatin
immunoprecipitation followed by high-throughput sequencing
(ChIP-Seq) (Fig. 1f). KEGG, REACTOME, and GO analyses of
genes associated with H3K27me3 converged on neuron-speciﬁc
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pathways as a major target of PRC2-dependent repression in this
ErbB2+ model (Supplementary Fig. 2d). This is consistent with
ﬁndings from the PyV mT model of luminal B breast cancer,
where genes involved in neuronal differentiation and function are
silenced by PRC221. Interestingly, however, only 20.2% of
H3K27me3-positive peaks in the genomes of NIC/c-Src+/+ cells
were mapped to genes and promoters, with the vast majority
(79.8%) found in intergenic, non-coding and genomic repeat
regions (Supplementary Fig. 2e). Comparison of transcripts up-
regulated in c-Src-deﬁcient cell lines with protein-coding genes
associated with H3K27me3 in control cell lines revealed an
overlap of 99 genes (Supplementary Fig. 2f). To examine the
relevance of this overlap, we derived a signature comprised of
genes transcriptionally activated in NIC/c-SrcL/L cells that
exhibited H3K27me3 within 20 kb of their transcriptional start
site (TSS) in two independent NIC/c-Src+/+ cell lines. We
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compared the expression of the corresponding transcripts (RNA-
Seq) in tumor biopsies from ERBB2+ breast cancer patients22,23
with matched EZH2 protein expression data, revealing a strong
negative correlation between EZH2 protein expression and
transcript levels of PRC2 target genes from the ErbB2+ GEMM
(Supplementary Fig. 2g), consistent with PRC2-mediated repres-
sion of these genes. Thus, while the de-repression of protein-
coding PRC2 target genes in NIC/c-SrcL/L cells is limited, a core
subset of these genes may be regulated by PRC2 in human
ERBB2+ breast cancer.
Overall, these ﬁndings indicate that c-Src ablation correlates
with reduced PRC2 function in ErbB2-driven breast tumors.
Strikingly, we observed that this correlated with a strong
reduction in the protein levels of Ezh2 and Suz12 in c-Src-
deﬁcient as compared to c-Src-positive tumors (Fig. 2a, Supple-
mentary Fig. 3a). Ezh2 and Suz12 mRNA levels were, however,
unaffected by c-Src ablation (Supplementary Fig. 3b), thereby
indicating that decreased expression of the corresponding
proteins was not caused by alterations in transcription and/or
mRNA stability. Proteasome inhibition moderately increased
Ezh2 protein expression in c-Src-proﬁcient, but not in c-Src-
deﬁcient cells (Supplementary Fig. 3c), indicating that increased
proteosomal degradation does not play a major role in the down-
regulation of PRC2 components upon c-Src ablation. We next
examined whether reduced PRC2 subunit expression occurred
through effects on protein synthesis. Puromycin labeling of
nascent proteins24 indicated that overall protein synthesis was
decreased upon c-Src loss (Fig. 2b), while puromycin incorpora-
tion into Ezh2 protein was signiﬁcantly reduced in c-Src-null cells
compared to c-Src-proﬁcient cells (Fig. 2c, Supplementary
Fig. 3d). To investigate further, we used sucrose density gradient
centrifugation to separate efﬁciently translated (associated with
heavy polysomes), non-efﬁciently translated (associated with light
polysomes) and non-translated (sub-ribosomal/mRNP fraction)
transcripts25 in extracts from c-Src-deﬁcient and control cells. In
agreement with the puromycylation assays, the number of
ribosomes engaged in polysomes was decreased in c-Src-
deﬁcient cells as compared to controls (Fig. 2d). Notably, c-Src
ablation shifted Ezh2 and Suz12 mRNAs from heavy polysomes
to sub-ribosomal/mRNP fractions (Fig. 2e) without reducing their
total mRNA levels (Supplementary Fig. 3e). In contrast, c-Src loss
did not affect the polysome distribution of mRNAs encoding β-
actin (Actb) or the Eed subunit of PRC2 (Fig. 2e), the expression
of which was not dependent on c-Src status (Fig. 2a). These
results demonstrate that c-Src loss in the context of ErbB2-driven
tumorigenesis down-regulates PRC2 function by impairing
translation of Ezh2 and Suz12 mRNAs.
c-Src activates mTORC1 to promote Ezh2 and Suz12 transla-
tion. Induction of eIF2α phosphorylation, which limits ternary
complex recycling, and inhibition of mTORC1 are two major
mechanisms of translational suppression26. Since we established
that c-Src loss does not alter eIF2α phosphorylation (Supple-
mentary Fig. 4a, b), we investigated effects on mTORC1. The
expression of mTORC1 components (mTOR, Raptor, mLST8,
PRAS40) and Akt-dependent phosphorylation of mTOR and
PRAS40 did not differ between c-Src-deﬁcient and control
tumors (Supplementary Fig. 4c). However, mTORC1-dependent
phosphorylation of Rps6 (ribosomal protein S6) and Eif4ebp1
(eukaryotic translation initiation factor 4E binding protein 1) was
reduced in ErbB2-driven tumors lacking c-Src (Fig. 3a, b).
Moreover, mTORC1 activation in response to amino acids,
serum/growth factors and glucose was markedly attenuated in
c-Src-deﬁcient tumor cells (Supplementary Fig. 4d–f), indicating
an intrinsic defect in their capacity to activate mTORC1. This was
consistent with the shifted polysome proﬁles of c-Src-deﬁcient
cells (Fig. 2d), reﬂecting reduced translation of an mTORC1-
dependent subset of mRNAs, as has been observed previously
when mTORC1 is inhibited27,28. Accordingly, we observed that
c-Src ablation decreased the translation of mRNAs known to
be regulated by the mTORC1/4E-BP axis, including Bcl2l1 (Bcl-
xL)29 and Ccnd327 (Supplementary Fig. 4g, h), mirroring the
observed effect on Ezh2 and Suz12 mRNAs. Re-expression of c-
Src in cells with conditional knockout of the endogenous alleles
restored mTORC1 activity and Ezh2/Suz12 protein expression
(Supplementary Fig. 4i). Likewise, silencing the translational
suppressor Eif4ebp1, which prevents the assembly of the eIF4F
complex and is inactivated via mTORC1-dependent phosphor-
ylation30, rescued Ezh2 protein expression in c-Src-deﬁcient cells
(Supplementary Fig. 4j). Moreover, mTOR inhibitors and silves-
trol, which inhibits eIF4A, the helicase subunit of the eIF4F
complex, strongly suppressed Ezh2 and Suz12 protein expression
in NIC/c-Src+/+ cells (Fig. 3c). Collectively, these ﬁndings
demonstrate that c-Src modulates the eIF4F-dependent transla-
tion of mRNAs encoding PRC2 components via the mTORC1/
4E-BP axis.
c-Src/mTORC1 controls PRC2 expression in human breast
cancer. In agreement with previous studies linking EZH2
expression with ErbB2 signaling31, ErbB2 kinase inhibition sig-
niﬁcantly diminished EZH2 protein expression in murine and
human cells in vitro, while ErbB2-driven pre-malignant mam-
mary lesions in vivo up-regulated Ezh2 protein expression in a
c-Src-dependent manner (Supplementary Fig. 5a, b). To examine
potential relationships between c-SRC activity, mTORC1 activa-
tion and PRC2 expression in human breast cancer, we analyzed a
tissue microarray (TMA) series containing primary samples from
a cohort of 292 patients, revealing that markers of SFK and
mTORC1 activation correlate positively with each other and with
EZH2 protein levels (Fig. 4a, b). We used a second, independent
Fig. 1 c-Src loss impairs tumor growth and PRC2 function in ErbB2+ breast cancer. a Kaplan–Meier analysis of mammary tumor onset in NIC mice with
wild-type Src alleles (NIC/c-Src+/+, n= 26) and mice heterozygous (NIC/c-Src+/L, n= 20) or homozygous (NIC/c-SrcL/L, n= 22) for the conditional Src
allele. **p < 0.01; logrank test. b Tumor burden was determined by weekly caliper measurements. *p < 0.05; one-way ANOVA with Tukey’s post-test.
c Control and c-Src-deﬁcient tumors were stained for Ki67 expression and incorporation of BrdU by immunohistochemistry (IHC). Top panels show
representative images. Scale bar represents 100 µm. Bottom panel shows quantiﬁcation of the percentage of Ki67 and BrdU-positive nuclei in tumors from
ﬁve independent mice of each genotype (minimum 10,000 total nuclei, *p < 0.05, **p < 0.01; unpaired, two-tailed Student’s t-test). d Left panel -
unsupervised hierarchical clustering analysis of genes differentially up-regulated (red) and down-regulated (blue) in NIC/c-SrcL/L tumors compared to NIC/
c-Src+/+ controls (n= 4 per genotype). Right panels - bioinformatic identiﬁcation of PRC2 targets among genes up-regulated in c-Src-deﬁcient tumors.
e Upper two panels show representative images of H3K27me3 staining of tumors from three independent NIC/c-Src+/+ and NIC/c-SrcL/L mice using IHC.
Scale bar represents 50 μm. Bottom panel shows quantitative nuclear staining intensity scored on a scale of 0–3 using Aperio image analysis software
(minimum 10000 nuclei counted per tumor, *p < 0.05, **p < 0.01; unpaired, two-tailed Student’s t-test). f Left panels show genome-wide proﬁling of the
H3K27me3 landscape in NIC/c-Src+/+ and NIC/c-SrcL/L tumor cells using ChIP-Seq, with red color intensity representing tag density. Representative tag
density plots (right top panel) and bar chart of the quantiﬁcation of H3K27me3 peaks in two independent cell lines of each genotype (right bottom panel)
are shown. All error bars throughout the ﬁgure are SEM
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TMA series containing 131 patient samples of ERBB2+ breast
cancer to conﬁrm these correlations speciﬁcally within this sub-
type (Fig. 4c). Functional relationships were assessed in a human
breast cancer setting by treating immunocompromised mice
bearing patient-derived xenografts (PDXs) established from two
ERBB2+ tumors with the SFK inhibitor Dasatinib or the active
site-directed mTOR inhibitor AZD2014, both of which are cur-
rently involved in multiple clinical trials. These inhibitors atte-
nuated tumor growth, with AZD2014 exerting the most
signiﬁcant effects (Supplementary Fig. 5c, d) and also reduced
mTORC1 activation (as assessed by EIF4EBP1 phosphorylation)
and the expression of EZH2 and SUZ12 proteins (Fig. 4d, e). We
conﬁrmed that these effects were not due to changes in the
expression of mTORC1 component proteins (Supplementary
Fig. 5e), although phosphorylation of mTOR (Ser2448) and
PRAS40 (Thr246) was reduced in Dasatinib- and AZD2014-
treated tumors. Reduced EZH2 expression and diminished
H3K27me3 in Dasatinib- and AZD2014-treated tumors were
validated by immunostaining (Fig. 4f, Supplementary Fig. 5f).
Allosteric and active site-directed mTOR inhibitors also reduced
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Fig. 2 c-Src is required for efﬁcient translation of PRC2 component mRNAs. a Immunoblot of PRC2 components in control and c-Src-deﬁcient tumors. Bar
chart shows quantiﬁcation of ﬂuorescent immunoblot data normalized to the loading control (Gapdh). b Protein synthesis in NIC/c-Src+/+ and NIC/c-SrcL/L
cells was assessed using puromycin incorporation with immunoblotting (Surface sensing of translation (SUnSET) assay). Images show detection of
puromycylated nascent proteins (left) and total cellular protein (right) following a 30min. treatment with puromycin (puro). Bar chart shows the
puromycin signal in each lane normalized to total protein levels (n= 5 per genotype). c Ezh2 was immunoprecipitated from NIC/c-Src+/+ and NIC/c-SrcL/L
cells treated as in b and newly synthesized Ezh2 was detected by immunoblotting with anti-puromycin (puro) and anti-Ezh2 antibodies.
Immunoprecipitation with non-speciﬁc IgG and Ezh2 immunoprecipitation from untreated cells were used as controls. Bar chart shows quantiﬁcation of the
puromycin signal in Ezh2 immunoprecipitations normalized to the total Ezh2 levels precipitated (n= 5 per genotype). d Representative polysome proﬁles of
two NIC/c-Src+/+ and two NIC/c-SrcL/L tumor cell lines. Proﬁles are representative of ﬁve biological replicates per genotype. e qRT-PCR analysis of mRNAs
isolated from polysome proﬁling of NIC/c-Src+/+ and NIC/c-SrcL/L tumor cell lines (5 biological replicates per genotype). In the box and whisker plots, the
center line represents the median, boundaries are the 25th and 75th percentiles and whiskers were calculated according to Tukey’s method. For all data,
*= p < 0.05 and **= p < 0.01 (unpaired, two-tailed Student’s t-test). For all bar charts, error bars are SEM
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EZH2 and SUZ12 protein expression in human ERBB2+ breast
cancer cell lines (SkBr3 and MDA-MB-361), but not a triple-
negative breast cancer (TNBC) cell line (MDA-MB-231), in a
manner commensurate with their ability to decrease EIF4EBP1
phosphorylation (Supplementary Fig. 5g). A similar decrease in
EZH2 and SUZ12 expression was observed in ERBB2+, but not
TNBC, cell lines treated with silvestrol or with two independent
SFK inhibitors, Dasatinib and eCF506, which exhibits greatly
enhanced speciﬁcity for the Src family32 (Supplementary Fig. 5g).
Finally, we examined EZH2 protein and mRNA expression and
EIF4EBP1 phosphorylation in an ERBB2+ patient cohort for
which both tissue sections and RNA-Seq data were available (as
in Supplementary Fig. 2g)22,23. Strikingly, we found that EZH2
protein expression did not signiﬁcantly correlate with EZH2
mRNA expression, but strongly correlated with phosphorylation
of EIF4EBP1, and hence activity of mTORC1 (Fig. 4g). This is
consistent with the pivotal role of the mTORC1/4E-BP axis in
regulating EZH2 expression in ERBB2+ breast cancer.
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Fig. 3 mTORC1 activity is impaired in ErbB2+ breast cancer cells lacking c-Src. a IF analysis of ErbB2 and phosphorylated forms of Rps6 and Eif4ebp1 in
control and c-Src-deﬁcient ErbB2+mammary tumors. Scale bars represent 50 µm. b Left panel – immunoblots of Rps6 and Eif4ebp1 phosphorylation in
control and c-Src-deﬁcient ErbB2+mammary tumors. Right panel - bar charts show quantiﬁcation of phosphorylated Rps6 and Eif4ebp1 proteins (n= 7
tumors per genotype). c Left - representative immunoblots of PRC2 expression and mTORC1 signaling in NIC/c-Src+/+ ErbB2+ breast cancer cells treated
with the indicated inhibitors for 24 h (Ev: everolimus, 10 nM; Torin 1, 250 nM; Silv: silvestrol, 25 nM). Right - Quantiﬁcation of Ezh2, Suz12 and Eed protein
levels in four independent cell lines following the indicated treatments. All data in this ﬁgure are presented as mean ± SEM, where *= p < 0.05 and
**= p < 0.01; unpaired, two-tailed Student’s t-test
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c-Src Drives PRC2 overexpression by regulating bioenergetics.
c-Src can cooperate with RTKs to activate Ras-MAPK and PI3K-
Akt pathways that act upstream of mTORC115,33,34. However,
phosphorylation of ErbB2, Egfr, ErbB3, Erk, and Akt was unaf-
fected by c-Src ablation in ErbB2+ tumors, as was Akt-dependent
phosphorylation of Tuberous Sclerosis Complex 2 (Tsc2) (Sup-
plementary Fig. 6a). Thus, in ErbB2-driven breast cancer, c-Src
appears to activate mTORC1 via a mechanism independent of
canonical RTK-driven pathways. Because mTORC1 is modulated
by metabolic inputs35 and c-Src is implicated in metabolic
regulation36,37, we examined known metabolic regulators of
mTORC1, including energy and amino acid levels. Strikingly,
phosphorylation of the central energy sensor 5′ adenosine
monophosphate-activated protein kinase (AMPK) and of its
substrate acetyl-CoA carboxylase (ACC) were elevated in c-Src-
deﬁcient, as compared to c-Src-positive, tumor tissue and cell
lines (Fig. 5a, b), correlating with an increased AMP:ATP ratio in
c-Src-deﬁcient cells (Fig. 5c, Supplementary Fig. 6b). c-Src-
deﬁcient cells also exhibited signiﬁcant reductions in the steady-
state levels of most amino acids (Supplementary Fig. 6c).
Although this was insufﬁcient to activate an amino acid starva-
tion response via GCN2-dependent eIF2α phosphorylation
(Supplementary Fig. 4a, b), it could potentially impair mTORC1
activation. However, AMPK-dependent phosphorylation of
d
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Raptor35 and Tsc238, two important mediators of
mTORC1 suppression by energy stress, was also elevated in c-Src-
deﬁcient tumors (Supplementary Fig. 7a). This led us to char-
acterize the bioenergetic state of c-Src-deﬁcient tumor cells in
more detail. c-Src ablation signiﬁcantly decreased the basal, ATP
synthesis-coupled and maximal oxygen consumption rates (OCR)
of ErbB2+ tumor cells, indicating an overall suppression of
respiration (Fig. 5d, e). Because mTORC1 promotes the transla-
tion of a subset of mRNAs encoding mitochondrial proteins,
leading to impaired mitochondrial function in cells where mTOR
is inhibited39, we examined the levels of known mTORC1-
dependent mitochondrial proteins (Atp5o, Tfam) and compo-
nents of the electron transport chain (ETC) in control and c-Src-
deﬁcient cells. Consistent with previous ﬁndings39, we observed
reduced expression of Atp5o and Tfam (Supplementary Fig. 7b)
and diminished levels of some ETC components including
Ndufb8 (complex I) and CoxIV (complex IV) in cells lacking c-
Src (Supplementary Fig. 7c). In contrast, no difference was
observed in the mitochondrial DNA to nuclear DNA (mtDNA:
nDNA) ratio, suggesting that alterations in mitochondrial protein
expression are not due to reduced mitochondrial biogenesis
(Supplementary Fig. 7d). In addition to effects on OXPHOS, c-Src
deﬁciency increased the extracellular acidiﬁcation rate (ECAR)
(Fig. 5e), which was corroborated by elevated glucose consump-
tion and lactate excretion (Fig. 5f). These ﬁndings argue that c-Src
deﬁciency reduces OXPHOS and elevates glycolysis, a metabolic
shift reﬂected in the gene expression proﬁles of c-Src-deﬁcient
tumors, which were enriched in signatures of glycolysis (Fig. 5g).
Changes in OCR and ECAR induced by c-Src deletion strongly
resemble those caused by biguanides40, which inhibit complex I
of the ETC. This reduces ATP synthesis and increases the AMP/
ATP ratio41,42, inactivating mTORC1 through both AMPK-
dependent and AMPK-independent mechanisms43,44. Linking
this metabolic remodeling to PRC2 component mRNA transla-
tion, analysis of human breast cancer cell translatomes27 showed
that the biguanide metformin, similarly to allosteric (rapamycin)
or active site-directed (PP242) mTOR inhibitors, reduced the
translational efﬁciency of EZH2 mRNA (Supplementary Fig. 7e).
Treatment of ErbB2-driven breast cancer cells with the biguanide
phenformin, which directly inhibits OXPHOS regardless of the
presence of c-Src, activated AMPK and inhibited mTORC1,
markedly reducing Ezh2 and Suz12 protein expression (Fig. 5h, i).
Multiple compounds targeting OXPHOS, including the unrelated
complex I inhibitor, rotenone, as well as the mitochondrial ATP
synthase inhibitor oligomycin A and the uncoupling agent CCCP
(Fig. 5h, i) replicated these effects. Moreover, direct allosteric
activation of AMPK by GSK621 and PF-06409577 also
suppressed Ezh2 and Suz12 protein expression concomitantly
with mTORC1 inhibition (Fig. 5h, i). None of these treatments
affected the expression of mTORC1 component proteins
(Supplementary Fig. 7f), although Akt-dependent phosphoryla-
tion of PRAS40 was reduced by inhibition of complex I or ATP
synthase. Collectively, these results demonstrate that, in the
context of ErbB2-driven breast cancer, c-Src loss reprograms
bioenergetics and induces energy stress, reducing mTORC1
activity and thereby down-regulating the translation of PRC2
components.
To determine whether the metabolic phenotypes of chronically
c-Src-deﬁcient ErbB2+ tumor cells are reproduced by acute c-Src
loss, we expressed Cre recombinase using adenoviral vectors in
ErbB2+ breast cancer cells with homozygous conditional Src
alleles. The loss of c-Src protein was complete at 96 h post-
infection (Supplementary Fig. 8a), correlating with an increased
AMP:ATP ratio, AMPK activation, mTORC1 suppression, and
reduced Ezh2 and Suz12 protein expression (Fig. 6a, b and
Supplementary Fig. 8b). Acute c-Src loss (Fig. 6c, d) or inhibition
of SFKs using Dasatinib or eCF506 (Supplementary Fig. 8c, d)
signiﬁcantly suppressed OXPHOS, including basal respiration
and respiration coupled to mitochondrial ATP synthesis.
However, in contrast to cells from c-Src-deﬁcient transgenic
tumors, extracellular acidiﬁcation, glucose consumption and
lactate excretion were also suppressed by acute c-Src ablation
(Fig. 6d, e). c-Src re-expression in c-Src-null cells elevated OCR to
control levels, indicating restoration of OXPHOS, which was
dependent on kinase activity since the effects were reversed by
SFK inhibitors (Supplementary Fig. 8d). SFK inhibitors did not
affect OCR in cells lacking c-Src expression, suggesting that their
effects were due to inhibition of c-Src (Supplementary Fig. 8d).
These observations conﬁrm that c-Src supports OXPHOS
capacity in ErbB2+ breast cancer cells, while arguing that
metabolic reprogramming towards enhanced glycolysis is an
adaptation that occurs during tumor evolution in the absence of
c-Src. To examine the role of AMPK in these phenotypes, we
genetically depleted its catalytic subunits (AMPKα1/α2). While
this partially restored OCR, it returned ECAR, glucose consump-
tion and lactate excretion to the levels seen in c-Src-proﬁcient
controls and rescued both mTORC1 signaling and expression of
Ezh2 and Suz12 proteins (Fig. 7a–e).
In addition to AMP binding to the AMPKγ subunit,
phosphorylation of Thr172 in the activation loop of the AMPKα
subunit, performed by LKB1 during energy stress and by
CAMKKβ in response to Ca2+ inﬂux, is an important event in
Fig. 4 c-Src and mTORC1 drive EZH2 protein expression in human breast cancer. a Tissue microarrays (TMAs) containing tumor samples from breast
cancer patients were stained with antibodies against EZH2, phosphorylated Src family kinases (SFK) and phosphorylated EIF4EBP1. Example images
indicate scoring by a specialist breast cancer pathologist (S.A.O.) with decreased scoring from left to right. Scale bar indicates 100 µm. b, c Associations
between staining intensities for each marker in a on two breast cancer TMAs. The Garvan-St. Vincent’s cohort b contained 292 samples from patients of all
subtypes, while the Royal Prince Albert Hospital (RPAH) cohort c contained samples from 131 HER2+ breast cancer patients. Rho and p values were
calculated using Spearman’s rank-order correlation analysis. d, e ERBB2+ breast cancer patient-derived xenografts GCRC1991 and GCRC2080 were
orthotopically implanted into NOD/SCID/gamma (NSG) mice which were treated with the SFK inhibitor Dasatinib (n= 7), the ATP-competitive mTOR
kinase inhibitor AZD2014 (n= 7) or vehicle (n= 6). EZH2 and SUZ12 levels and the activity of SFK and mTORC1 were determined by immunoblotting of
tumor tissue lysates d. Bar charts e show quantiﬁcation of EZH2 and SUZ12 levels normalized to the loading control (ACTB) using ﬂuorescent
immunoblotting (n= 4, *p < 0.05, unpaired Student’s t-test vs vehicle). f Immunoﬂuorescence analysis of EZH2 expression and phosphorylation of
EIF4EBP1 in ERBB2+ PDX tumors following administration of inhibitors or vehicle control. Bottom right panel - digital pathology analysis software (HALO)
was used to quantify EZH2 staining in tumor cells (positive for human-speciﬁc pan-cytokeratin staining). Scale bars indicate 100 µm (minimum 10000 cells
counted per tumor, *p < 0.05, unpaired, two-tailed Student’s t-test). g EZH2 protein expression and EIF4EBP1 phosphorylation were quantiﬁed in samples
from ERBB2+ breast cancer patients using immunoﬂuorescence with digital pathology analysis as in f. Pearson’s correlation analysis was used to correlate
these parameters with each other and with EZH2 mRNA levels (RNA-Seq reads) determined in the same samples. Left panel shows the correlation
between EZH2 mRNA and protein, middle panel shows the correlation between EZH2 protein and phospho-EIF4EBP1, right panel shows the correlation
between EZH2 mRNA and phospho-EIF4EBP1. All error bars in this ﬁgure are SEM
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AMPK activation45. Notably, CAMKKβ was recently implicated
in AMPK activation during amino acid starvation45,46. To
examine the contributions of these regulators to AMPK activation
in NIC/c-Src+/+ and NIC/c-SrcL/L cells, we used the speciﬁc
Camkkβ inhibitor STO-60947 (Supplementary Fig. 9a) and
silenced Lkb1 expression with three independent siRNAs
(Supplementary Fig. 9b). While Camkkβ inhibition mainly
affected AMPK activity in NIC/c-Src+/+ cells, silencing Lkb1
reduced the phosphorylation of AMPK and ACC in both NIC/c-
Src+/+ and NIC/c-SrcL/L cells. These ﬁndings are in agreement
with a previous study using the same model, where Lkb1 deletion
abolished the majority of AMPK activity40. However, these results
may also be consistent with Lkb1 and Camkkβ acting in parallel
or cooperatively during AMPK activation48.
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Ezh2 is required for ErbB2-driven mammary tumorigenesis.
To directly address the requirement for PRC2/Ezh2 in ErbB2-
driven breast cancer progression, we performed a series of
experiments where Ezh2 was ablated or down-regulated in
ErbB2+ breast cancer models. Remarkably, conditional deletion
of Ezh2 (Ezh2L/L)2 in an ErbB2-driven GEMM induced a near-
complete block in mammary tumorigenesis, with focal tumors
arising after a long latency and with signiﬁcantly reduced pene-
trance after over a year of follow-up (Fig. 8a). Ezh2 plays a
complex role during mammary development, with studies
showing that it regulates mammary epithelial stem cell
populations49,50 and that its deletion accelerates51 or delays49,50
pubertal ductal outgrowth. Using MMTV-Cre/Ezh2L/L mice and
MMTV-Cre/Ezh2+/+ controls on a pure FVB/N genetic back-
ground, we determined that mammary epithelial Ezh2 ablation
transiently delayed outgrowth of the mammary ductal tree, in
agreement with previous studies49. MMTV-Cre/Ezh2L/L mice
exhibited normal ductal architecture and no signiﬁcant difference
in outgrowth by 12 weeks of age (Supplementary Fig. 10a).
Whole-mounted mammary glands from 16-week-old NIC/Ezh2L/
L mice contained a complete ductal tree with a normal gross
histological appearance, while age-matched control NIC/Ezh2+/+
mice manifested visible mammary epithelial lesions (Supple-
mentary Fig. 10b). ErbB2-positive/Ezh2-null epithelial cells in
normal ducts and small hyperplastic lesions in mammary glands
from NIC/Ezh2L/L mice (Fig. 8b) were largely Ki67-negative,
whereas prominent Ki67 staining was observed in ErbB2-posi-
tive/Ezh2-positive cells in age-matched control NIC/Ezh2+/+
mammary glands (Fig. 8c, d). These ﬁndings suggest that, while
Ezh2-deﬁcient mammary epithelial cells can be transformed by
Fig. 5 Impaired OXPHOS and induction of energy stress reduce PRC2 expression. a IF analysis of ErbB2 expression and ACC phosphorylation in
c-Src-proﬁcient and -deﬁcient ErbB2+mammary tumors. Representative images from ﬁve tumors of each genotype. Scale bar represents 50 µm.
b Representative immunoblot showing AMPK activation and ACC phosphorylation in NIC/c-Src+/+ and NIC/c-SrcL/L cell lines. c LC/MS analysis of AMP:
ATP ratios in NIC/c-Src+/+ and NIC/c-SrcL/L cell lines (3 cell lines per genotype). d Basal, maximal (FCCP), ATP-synthesis-coupled (Oligomycin A), and
non-mitochondrial (rotenone/antimycin A) oxygen consumption rates (OCRs) of NIC/c-Src+/+ and NIC/c-SrcL/L cells. Representative of 5 cell lines per
genotype. e Quantiﬁcation of basal OCR and extracellular acidiﬁcation rates (ECAR) of NIC/c-Src+/+ and NIC/c-SrcL/L cell lines. (5 cell lines per genotype).
f Glucose consumption and lactate levels in conditioned media from NIC/c-Src+/+ and NIC/c-SrcL/L cell lines (5 cell lines per genotype). g Representative
plot and heatmap from GSEA showing increased expression of genes associated with glucose metabolism in NIC/c-SrcL/L tumors relative to NIC/c-Src+/+
controls (4 tumors per genotype). h NIC cells were treated for 24 h with the mitochondria-targeting agents phenformin (Phen, 100 µM), rotenone (Rote,
0.5 µM), Oligomycin A (OligoA, 1 µM) or CCCP (1 µM) or the allosteric AMPK activators GSK621 (GSK, 25 µM) or PF-06409577 (PF, 50 µM) for 24 h.
Representative immunoblots of PRC2 component expression, AMPK and mTORC1 pathway activation are shown. i Quantiﬁcation of Ezh2 and Suz12
protein expression in four independent cell lines treated as in h. All bar charts show mean±SEM, with *= p < 0.05 and **= p < 0.01 (unpaired, two-tailed
Student’s t-test)
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Fig. 6 Acute c-Src ablation diminishes both OXPHOS and glycolysis. a ErbB2+murine breast cancer cells with wild-type (c-Src+/+) or conditional
(c-SrcL/L) Src alleles were infected with adenoviruses bearing Cre recombinase or LacZ. Immunoblots show c-Src expression, mTORC1 and AMPK signaling
and PRC2 component expression at 96 h post-infection. Data are representative of 3 cell lines per genotype. b LC/MS analysis of AMP:ATP ratios in
control (LacZ) and Cre-expressing cell lines (n= 3 cell lines per genotype). c Basal, maximal (FCCP), ATP-synthesis-coupled (Oligomycin A), and non-
mitochondrial (rotenone/antimycin A) oxygen consumption rates (OCRs) of ErbB2-expressing c-Src+/+ and c-SrcL/L breast cancer cell lines (n= 2 per
genotype) infected with Cre or LacZ adenoviruses. Representative of 2 cell lines per genotype. d Basal OCR and ECAR of c-Src+/+ and c-SrcL/L cell lines
infected with Cre adenoviruses, expressed as a percentage of the rate measured in the LacZ control for each cell line. e Glucose consumption and lactate
levels in conditioned media from c-Src+/+ and c-SrcL/L cell lines infected with Cre adenoviruses, expressed as a percentage of levels observed in LacZ-
expressing controls. All bar charts show mean ±SEM, with *= p < 0.05 and **= p < 0.01 (unpaired, two-tailed Student’s t-test)
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ErbB2, tumor progression in the absence of Ezh2 is blocked at an
early hyperplastic stage. To examine the role of Ezh2 methyl-
transferase activity in ErbB2-driven mammary tumor progres-
sion, we treated 10 week-old MMTV-NIC mice with the Ezh2
inhibitor GSK126, which competes with S-adenosylmethionine
(SAM) for binding to the EZH2 SET domain52. After 10 weeks of
treatment, a largely normal ductal tree was observed in mice
treated with GSK126, with evidence of small hyperplastic lesions,
morphologically similar to those observed in the Ezh2 genetic
knockout, which demonstrated loss of H3K27me3 (Fig. 8e and
Supplementary Fig. 10c). In contrast, the mammary glands of
vehicle-treated mice had undergone widespread transformation,
with abundant hyperplastic and adenomatous lesions exhibiting
H3K27me3 (Fig. 8e and Supplementary Fig. 10c). As with Ezh2
genetic ablation, this phenotype correlated with signiﬁcantly
reduced Ki67 expression in the ErbB2-positive mammary epi-
thelial cells of mice treated with the Ezh2 inhibitor (Fig. 8f).
These data indicate that Ezh2 has pivotal functions in ErbB2-
driven mammary tumorigenesis that are unlikely to be related to
confounding effects on mammary gland development. To test the
effect of downregulating Ezh2 expression, rather than complete
loss of function through conditional gene targeting, and to
determine effects on the growth of established tumor cells, we
stably silenced Ezh2 in cells from the MMTV-NIC model. This
signiﬁcantly reduced proliferation in vitro and impaired ortho-
topic tumor growth in vivo (Fig. 9a, b). Two structurally
unrelated Ezh2 inhibitors, GSK126 and EPZ643853, also sig-
niﬁcantly impaired the proliferation of ErbB2-driven breast
cancer cells in vitro (Fig. 9c). In contrast to NIC/c-Src+/+ cells,
the growth of NIC/c-SrcL/L cells, which have reduced Ezh2 and
Suz12 expression and diminished PRC2 activity, was not
signiﬁcantly affected by GSK126 (Supplementary Fig. 10d).
Collectively, these data conﬁrm that Ezh2 overexpression and
catalytic activity strongly promote the proliferation of ErbB2-
driven breast cancer cells.
Discussion
Persistent activation of mTORC1, a master coordinator of cellular
metabolism and growth, reprograms the translatome to support
the malignant state28,54. By enhancing eIF4F-dependent transla-
tion, mTORC1 activation increases the synthesis of mitochondrial
proteins39 and transcription factors promoting mitochondrial
biogenesis54,55, thereby stimulating OXPHOS. mTORC1 also
increases glycolytic ﬂux56,57 and drives the translation of mRNAs
encoding transcription factors that up-regulate glycolysis,
including HIF-1α58. Here, we show that mTORC1 activation
shapes the transcriptome at the epigenetic level by promoting the
translation of PRC2 components, establishing an epigenetic
landscape underpinning the progression of ErbB2-driven mam-
mary tumors (Fig. 9d). These ﬁndings place PRC2 components
within the spectrum of mRNAs up-regulated by mTORC1 to
drive unrestrained cell growth and proliferation.
We found that mTORC1 activation in ErbB2+ breast cancer
cells was exquisitely sensitive to c-Src activity through a tumor
cell-intrinsic mechanism involving bioenergetic reprogramming,
rather than modulation of growth factor-dependent pathways
such as PI-3K/Akt33,34 or changes in the expression of
mTORC1 subunits. Dasatinib-induced changes in the phos-
phorylation of mTORC1 subunits (mTOR Ser2448 and PRAS40
Thr246) in PDX models (Supplementary Fig. 9e) may be due to
inhibition of kinases other than c-Src that act upstream of PI-3K/
Akt, as these effects are not observed in systems where c-Src is
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targeted speciﬁcally. Overall, our data are consistent with pre-
vious reports suggesting that c-Src stimulates mitochondrial ATP
production36,37. Although cells evolving without c-Src in vivo
displayed a metabolic shift toward glycolysis, they were unable to
alleviate energy stress. Since mTORC1 activity is coupled tightly
to energy sufﬁciency35, the ability of c-Src to bolster mitochon-
drial ATP generation facilitates mTORC1-dependent translation
of PRC2 components and ErbB2-driven tumorigenesis. In
accordance with previous ﬁndings39, we observed reduced
expression of the mitochondrial transcription factor Tfam and the
ATP synthase (complex V) subunit Atp5o, as well as components
of ETC complexes I and IV, in c-Src-deﬁcient cells. Thus, inhi-
bition of mTORC1 due to c-Src loss may exacerbate mitochon-
drial dysfunction, further contributing to energy stress. The
precise mechanisms by which c-Src promotes OXPHOS remain
elusive, as putative mitochondrial substrates are largely incon-
sistent between different studies and c-Src lacks a mitochondrial
targeting sequence (MTS), making its means of accessing mito-
chondrial targets unclear. Notably, the non-receptor tyrosine
kinase c-Abl, also lacking an MTS, reaches mitochondrial sub-
strates through interactions with MTS-containing proteins59 or
phosphorylates substrates exposed at the cytosolic surface of the
outer membrane60. Future studies will aim to identify and char-
acterize analogous mechanisms mediating metabolic control by
c-Src in ErbB2+ breast cancer cells.
In cells where PRC2 exerts pro-tumorigenic functions, linking
its expression with energy sensing mechanisms may contribute to
metabolic checkpoints that facilitate proliferation when ATP
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levels are sufﬁcient and suppress proliferation during energy
stress. This regulation often involves AMPK, which our results
indicate is critical in suppressing mTORC1 activity and PRC2
expression in c-Src-deﬁcient cells, as well as in stimulating
glycolysis, which is another established metabolic output of
AMPK activity61. We show that OXPHOS is highly responsive to
acute targeting of c-Src and its re-expression in deﬁcient cells.
Interestingly, however, acute c-Src deletion or kinase inhibition in
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wild-type cells did not replicate the up-regulation of glycolysis
seen in chronically c-Src-deﬁcient cells, but suppressed baseline
levels of glycolysis, which is consistent with previous ﬁndings on
phosphorylation of glycolytic regulators and enzymes by SFKs62.
Considered with the evidence for transcriptional up-regulation of
glucose metabolism, these data argue that c-Src-deﬁcient tumors
acquire enhanced glycolytic capacity through genetic and/or
epigenetic changes establishing AMPK-dependent stimulation of
glycolysis61 during tumor evolution in vivo. We also observed
signiﬁcantly reduced steady-state amino acid levels in c-Src-
deﬁcient ErbB2+ cells, potentially activating another critical
metabolic checkpoint inactivating mTORC1. A recent study has
implicated c-Src in amino acid sensing through inhibition of the
GATOR1 complex, which inactivates mTORC1 under low amino
acid conditions63. AMPK activation is also implicated in the
response to amino acid starvation via Ca2+ inﬂux and
CAMKKβ46. Overall, our data indicate that energy stress, rather
than amino acid starvation or sensing, is the primary driver of
AMPK activation and mTORC1 suppression in c-Src-deﬁcient
ErbB2+ cells. However, it is possible that multiple metabolic
alterations, including changes in amino acid metabolism, could
contribute to these phenotypes.
PRC2 exerts highly context-speciﬁc effects in cancer, with
activating and loss-of-function mutations of its components
supporting oncogenic and tumor suppressive functions, respec-
tively4. EZH2 overexpression was linked to the transformed
phenotype initially in solid tumors including prostate cancer and
breast cancer. However, subsequent studies suggested that Ezh2 is
dispensable for breast carcinogenesis6,64 or that Ezh2 inhibition is
tumor-promoting7. These inconsistencies may stem from breast
cancer heterogeneity, which presents a variety of contexts that
determine the requirement for PRC2 activity. For example, Ezh2
appears to be dispensable for tumorigenesis in some models of
TNBC7,64. Here, in contrast, we show that Ezh2 is required for
tumor progression beyond an early hyperplastic stage in models
of ErbB2-positive breast cancer and for proliferation and tumor
growth in established ErbB2+ breast cancers. Such differences
between breast cancer subtypes may be explained by differing
cells of origin4, which, in conjunction with interactions between
subtype-speciﬁc genetic events, signaling and metabolism, result
in distinct requirements for PRC2-mediated gene silencing.
Transcriptomic and epigenomic proﬁling conﬁrmed the sig-
niﬁcant loss of PRC2 function in c-Src-deﬁcient tumor cells.
Interestingly, our analyses revealed that the vast majority of
H3K27me3 in NIC/c-Src+/+ cells occurs in non-coding regions of
the genome, while few PRC2-silenced protein-coding genes in
control cells were transcriptionally activated in c-Src-deﬁcient
cells. This may indicate that c-Src-deﬁcient cells have adopted
alternative mechanisms to maintain transcriptional silencing of
genes originally targeted by PRC2. Regulation of non-coding
RNAs, including retrotransposons and repeat regions, is
increasingly recognized as an important function of PRC265,66
and is an interesting avenue for further study in the context of
breast cancer.
While EZH2 is an emerging therapeutic target in cancer52, it
also plays vital roles in normal stem cells and tissue
homeostasis1,4. Identifying mechanisms underlying EZH2 over-
expression in cancer, such as those described here, may allow
selective targeting of aberrant PRC2 activity while minimizing
toxicity in normal tissues. Importantly, the diversity of PRC2
functions in different cancers necessitates careful characterization
of its roles in speciﬁc tumor types to identify appropriate contexts
for targeting PRC2, either directly or through its upstream reg-
ulators. Our ﬁndings suggest that such strategies may be bene-
ﬁcial for patients with ERBB2-overexpressing tumors, where lack
of response and the development of resistance to ERBB2-targeted
therapies present signiﬁcant obstacles to improving patient
outcomes.
Methods
Animal models. All experiments involving mice were carried out under an Animal
Use Protocol approved by the McGill University Downtown Campus Facility
Animal Care Committee (FACC), a branch of the McGill University Animal Care
Committee (UACC). All experiments were conducted in accordance with McGill
University and Canadian Council on Animal Care (CCAC) ethical guidelines. The
MMTV-NIC model, Src and Ezh2 conditional mice have been described
previously2,17,18. Cohorts of female MMTV-NIC mice carrying wild-type or con-
ditional alleles of Src and Ezh2 on a pure FVB/N genetic background were mon-
itored for mammary tumor formation by twice weekly palpation. Female
littermates were group housed under SPF conditions with a 12 h day/night cycle
and ad libitum access to food and water. Once detected, tumors were measured
weekly using calipers until they had reached a volume of 2.5 cm3 in size for a single
mass or a total volume of 5 cm3 for multifocal tumors, at which point mice were
euthanized in accordance with approved facility protocols. For studies of Ezh2
targeted therapy in the MMTV-NIC model (Fig. 8), mice were used prior to the
onset of palpable tumors (treatment beginning at 10 weeks of age).
For Patient-Derived Xenograft models, the recipients were female NOD/SCID/
gamma (NSG) immunocompromised mice (purchased from Charles River). For
propagation, tumors were excised, cut into pieces of ~8 mm3 and re-implanted into
the left inguinal mammary fat pads of NSG mice.
For orthotopic transplantation of cell lines derived from the MMTV-NIC tumor
model, the recipients were female NCr athymic nude immunocompromised mice
(purchased from Taconic). In total 5 × 105 tumor cells were suspended in 30 µl of
PBS and injected unilaterally into the left inguinal fat pad. Tumor growth was
measured by twice-weekly caliper measurements.
Human subjects. For TMA studies, two cohorts of breast cancer patients were
used. All patients provided written, informed consent. The studies were approved
by the Research Ethics Ofﬁce/Institutional Review Board (IRB) of the Faculty of
Medicine, McGill University (Study #A07-M40-15B) and of the Royal Prince
Albert Hospital (HREC/15/RPAH/531 & X15-0388) and the Garvan Institute/St.
Vincent’s Hospital (HREC/08/CIPHS/62). The Garvan/St.Vincent’s Hospital
cohort consists of 292 female breast cancer patients with a median age of 54 years
who were diagnosed with invasive ductal adenocarcinoma between February 1992
and August 2002. Formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue blocks were
retrieved from St Vincent’s Public Hospital (Sydpath) and St Vincent’s Private
Hospital (Douglas Hanly Moir Pathology), Sydney, Australia, and used to construct
TMAs consisting of 2 cores of approximately 1 mm diameter per patient
(approximately 80 cores per slide). Detailed information regarding the clin-
icopathologic characteristics of this cohort has been published elsewhere67.
The Royal Prince Alfred Hospital (RPAH) HER2-positive cohort was derived
from a larger cohort of 700 patients diagnosed with invasive ductal
adenocarcinoma at the Royal Prince Albert Hospital, Sydney, Australia68. FFPE
tumor samples and patient ﬁles were retrieved from the Department of Tissue
Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Concord
Repatriation General Hospital tumor archives (Sydney, Australia) and were
reviewed by a specialist breast pathologist. A HER2+ subset consisting of 131
female breast cancer patients with a median age of 53.61 years was selected and
TMAs were constructed using three 1 mm cores taken from different areas of each
tumor. HER2 status was conﬁrmed via immunohistochemistry. IHC= 0 or 1, 2+
cases were conﬁrmed by HER2 ﬂuorescence in-situ hybridization (FISH).
For matched immunoﬂuorescence (IF) and mRNA (RNA-Seq) analysis of
patient samples (Fig. 4), frozen sections of primary tumor biopsy material from a
cohort of HER2+ patients were obtained and previously published RNA-Seq data
were used22,23. Patients were from two independent, multi-site clinical trials (03-
311, NCT00148668; and BrUOG 211B, NCT00617942) and had provided prior
written, informed consent. Tissue collection for this study was approved by the
Institutional Review Boards (IRBs) of the Dana Farber Cancer Institute and the
Yale Comprehensive Cancer Centre (03-311) or the Brown University Oncology
Group, the Yale Comprehensive Cancer Centre and the City of Hope
Comprehensive Cancer Center (BrUOG 211B).
PDX models were established from tumor samples collected with informed
consent from hospitals of the McGill University Health Centre, Montreal, QC.
Tissue collection was performed under a protocol approved by the Research Ethics
Ofﬁce/Institutional Review Board (IRB) of the Faculty of Medicine, McGill
University.
Primary cell cultures and cell lines. This study used primary cultures and cell
lines derived from mammary tumors arising in female MMTV-NIC transgenic
mice18. Tumors at 8 weeks post palpation were processed with a McIlwain tissue
chopper (Mickle Laboratory Engineering), dissociated in collagenase B (Roche,
11088831001) and Dispase II (Roche, 4942078001) (2.4 mg/ml each) for 1 h at
37 °C, washed three times with PBS/1mM EDTA and plated in Complete Media,
consisting of DMEM (Wisent, 319-005-CL) supplemented with 5% FBS (Wisent,
080-150), 5 ng/ml EGF (Wisent, 511-110-UM), 1 μg/ml Hydrocortisone (Sigma,
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H4001), 5 μg/ml Insulin (Wisent, 511-016-UG) and 35 μg/ml Bovine Pituitary
Extract (BPE – Hammond CellTech, 1078-NZ). Cells were grown in a humidiﬁed,
5% CO2, 37 °C incubator in Complete Media. The genotype of murine cell lines
was authenticated by PCR on genomic DNA to detect the presence of the MMTV-
NIC transgene and the presence of wild-type and LoxP-ﬂanked conditional alleles
(oligonucleotide details in Supplementary Data 1) and also by immunoblotting to
detect the expression of ErbB2, Cre recombinase and c-Src proteins. Cells were
routinely tested (every 2 weeks) for mycoplasma using the MycoAlert kit (Lonza,
LT07-118) according to the manufacturer’s instructions. All cells used in this study
were negative for mycoplasma contamination.
Human cell lines. Lentiviruses were produced using 293T cells purchased from
ATCC. These cells were used at early passage (less than 10 passages) and were not
authenticated. SkBr3, MDA-MB-361, and MDA-MB-231 (human breast cancer)
cells were purchased from ATCC, used at early passage and were not authenticated.
Cells were routinely tested (every 2 weeks) for mycoplasma using the MycoAlert kit
(Lonza) according to the manufacturer’s instructions. All cells used in this study
were negative for mycoplasma contamination.
Lentiviral Transduction. Lentiviruses bearing shRNA against Ezh2 and Eif4ebp1
were produced in 293T cells (ATCC) co-transfected with the vectors pMD2.G and
psPAX2, gifts from Dr. Didier Trono (Addgene plasmids #12259 and #12260).
Lipofectamine 3000 (Invitrogen, L3000075) was used for transfection according to
the manufacturer’s instructions and virus-containing media was harvested and
ﬁltered through a 0.45 µm ﬁlter at 24 and 48 h post-transfection. MMTV-NIC cells
were transduced in the presence of 10 µg/ml polybrene (Sigma, 107689). Trans-
duced cell lines were selected and maintained in Complete Media with 2 μg/ml
puromycin (BioShop, PUR333).
siRNA Transfection. MMTV-NIC cells were transfected with siRNAs targeting
Lkb1 or a negative control siRNA (see Supplementary Data 1 for oligo informa-
tion) at a ﬁnal concentration of 5 nM using Lipofectamine 3000 according to the
manufacturer’s instructions. Cells were lysed for immunoblotting 72 h after
transfection.
Drug Treatment of Cell Lines. Everolimus (LC Laboratories, E-4040), Torin 1 (LC
Laboratories, T-7887), and silvestrol (MedChem Express, HY-13251) were recon-
stituted in DMSO and cells were treated at the concentrations indicated in the
ﬁgures for 24 h. Phenformin (MedChem Express, HY-16397A) and eCF50632
(provided by Dr. Asier Unciti-Broceta) were reconstituted in sterile water, while
rotenone (Toronto Research Chemicals, R700580), oligomycin A (Sigma, 75351),
CCCP (Tocris, 04-525-00), GSK621 (Adooq, A15896), PF-06409577 (Tocris, 6114),
and Dasatinib (LC Laboratories, D-330) were reconstituted in DMSO. Cells were
treated at the concentrations indicated in the ﬁgures for 24 h. For treatment with
GSK126 (Custom synthesis, Mercachem) and EPZ6438 (MedChem Express, HY-
13803) (both reconstituted in DMSO), cells were treated at a concentration of 2 µM
for 7 days, with media and drug replenished on day 3 and day 6. Cells were seeded
into 96-well plates for use in proliferation assays or histones were extracted for
immunoblotting analysis on day 7.
Preclinical studies in PDX models. Following transplantation of PDX tumors,
mice were randomly assigned to treatment groups and monitored for tumor
growth by twice-weekly palpation. Once tumors had reached a size of 5 mm × 5
mm (~65 mm3) treatment was initiated. Dasatinib (10 mg/kg) and AZD2014 (20
mg/kg – MedChem Express, HY-15247) were formulated in 30% Sulfobutylether-
β-cyclodextrin (MedChem Express, HY-17031) in water and administered by daily
oral gavage. Mice were weighed twice weekly and doses were adjusted according to
bodyweight. Tumor growth was measured by twice-weekly caliper measurements.
Drug administration, data collection and data analysis were performed by separate
individuals who were blinded with respect to the treatment group of each mouse.
Preclinical studies in GEMMs. 10 week-old MMTV-NIC mice were randomly
assigned to receive GSK126 (300 mg/kg, dissolved in 20% sulfobutylether-β-
cyclodextrin in water) or vehicle control (20% sulfobutylether-β-cyclodextrin in
water) by intraperitoneal injection every 48 h. Mice were euthanized at 20 weeks of
age, following 10 weeks of treatment. At this time point,MMTV-NICmice typically
exhibit pre-malignant mammary epithelial lesions and small, pre-palpable mam-
mary tumors. Drug administration, data collection and data analysis were per-
formed by different individuals who were blinded with respect to the treatment
group of each mouse.
Histology, Immunostaining and Tissue Microarrays (TMA). Tumors or
mammary glands were ﬁxed in 10% neutral buffered formalin (Leica, 3800600) for
24 h and embedded in parafﬁn for sectioning. Sections were cut at 4um, depar-
afﬁnized in xylene and antigen retrieval was performed with 10 mM sodium citrate
(pH 6) using a pressure cooker. Sections were then blocked with 10% Power Block
(BioGenex, HK083) in PBS for 10 min at room temperature. Sections were incu-
bated with primary antibody at 4 °C overnight. For immunoﬂuorescence, sections
were incubated with secondary antibodies for one hour at room temperature,
followed by DAPI (4′,6-Diamidino-2-Phenylindole, Dihydrochloride, Thermo-
Fisher, D1306) for 15 min, washed three times in PBS and mounted in Immu-
Mount (Thermo Scientiﬁc, 9990412). Immunostained samples were imaged using a
Zeiss LSM800 confocal microscope and analyzed with ZEN software. For quanti-
ﬁcation of Ki67 positivity (Fig. 8d), ﬁve independent ﬁelds of view in mammary
gland sections from four mice per genotype were analyzed. A total of 2600 cells in
ErbB2-positive lesions from NIC/Ezh2+/+ mice and 1200 cells in ErbB2-positive
lesions from NIC/Ezh2L/L mice were counted. For quantiﬁcation of Ezh2 positivity
in PDX models (Fig. 4g) and Ki67 positivity inMMTV-NIC mice receiving GSK126
or vehicle control (Fig. 8g), HALO software (Indica Labs) was used according to
the manufacturer’s instructions to speciﬁcally analyze human pan-cytokeratin-
positive tumor cells in PDX models (Fig. 4g) or ErbB2-positive mammary epithelial
cells in MMTV-NIC mammary glands (Fig. 8g), excluding stroma and areas of
necrosis. A minimum of 5000 (PDX models) or 1000 (MMTV-NIC mammary
glands) cells per mouse was counted.
For IHC, sections were deparafﬁnized and blocked as above and endogenous
peroxidase activity was quenched by incubation in 3% hydrogen peroxide for 20
min. Sections were incubated with primary antibody overnight at 4 °C, washed
three times in PBS and then incubated with ImmPRESS HRP polymer reagents to
detect rabbit and mouse antibodies (Vector Elite, MP-7401 and MP-7402,
respectively) according to the manufacturer’s instructions. After three further
washes in PBS, IHC staining was visualized using the SignalStain DAB Substrate kit
(Cell Signaling, 8059S) according to the manufacturer’s instructions. Sections were
then counterstained with hematoxylin, dehydrated, and mounted with Clearmount
(Invitrogen, 10058832). Images were acquired using an Aperio-XT slide scanner
and analyzed using a nuclear staining algorithm in the associated software (Aperio
Technologies).
TUNEL (Apoptag Peroxidase In Situ Apoptosis Detection Kit, EMD Millipore,
S7100) was performed on tissue sections as described above and according to the
manufacturer’s instructions
For IHC analysis of TMA slides, four-micron sections were cut from each TMA,
mounted on SuperFrost Plus glass slides and baked for 2 h at 79 °C. IHC was
performed as described above. Nuclear (EZH2) and cytoplasmic (phospho-
EIF4EBP1 and phospho-Src family kinases) staining was assessed by an
experienced breast pathologist (S.A.O.). For each marker, both a staining intensity
score (0: negative, 1+: weak, 2+: moderate and 3+: strong) and a percentage of
positively stained cells were assigned to each core. For each core, a histoscore (H
score) was derived by multiplying the intensity score by the percentage of positively
stained cells for each marker. To determine correlations between the histoscores for
the markers, a Spearman’s rank correlation test was applied.
The following primary antibodies were used for immunostaining techniques at
the indicated dilutions: Ki-67 - Abcam, ab38113, 1/500; BrdU - Cell Signaling,
5292, 1/100; H3K27me3 (C36B11) - Cell Signaling, 9733, 1/100; Ezh2 (D2C9) XP -
Cell Signaling, 5246, 1/500; ErbB2/c-Neu (AB3) - Calbiochem, OP15, 1/100; P-4E-
BP1 Thr37/46 - Cell Signaling, 2855, 1/100; P-Rps6 Ser 240/244 - Cell Signaling,
5364, 1/500; P-AMPK Thr172 - Cell Signaling, 2535, 1/50; P-ACC Ser79 - Cell
Signaling, 3661, 1/100; P-Src Family Kinase Tyr416 - Cell Signaling, 2101, 1/100.
The following secondary antibodies were used for immunostaining techniques:
For IHC –ImmPRESS HRP polymer reagents as described above, For IF - Alexa
Fluor 488 Donkey anti-Rabbit – Fisher Scientiﬁc, A21206; Alexa Fluor 555 Donkey
anti-Rabbit – Fisher Scientiﬁc, A31572; Alexa Fluor 488 Donkey anti-Mouse –
Fisher Scientiﬁc, A21202; Alexa Fluor 555 Donkey anti-Mouse – Fisher Scientiﬁc,
A31570; Alexa Fluor 647 Donkey anti-Mouse – Fisher Scientiﬁc, A31571; Alexa
Fluor 647 Goat anti-Guinea pig – Fisher Scientiﬁc, A21450. All ﬂuorescent
secondary antibodies were used at a dilution of 1/1000.
Mammary gland whole mounts. Mammary glands (number 4, inguinal) were
excised, placed on glass slides and ﬁxed overnight in acetone. Glands were stained
in haematoxylin for 24 h, destained in 70% ethanol/1% HCl, washed in 100%
ethanol, dehydrated overnight in xylenes, and mounted using Permount (Fisher
Scientiﬁc, SP15-100).
Protein extraction and immunoblotting. Freshly excised tumor tissue was
immediately ﬂash-frozen in liquid nitrogen, crushed with a mortar and pestle
under liquid nitrogen, allowed to thaw brieﬂy and then lysed in ice-cold RIPA
buffer (Tris–HCl 50 mM, pH 7.4, sodium chloride 150 mM, 1% Nonidet P-40, 1%
sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 0.5 mM AEBSF (Santa Cruz, sc-
202041), 25 mM β-glycerophosphate (Sigma, G5422), 1 mM sodium orthovanadate
(BioShop, SOV664), and 10 mM sodium ﬂuoride (Sigma, S7920)). Cultured cells
were lysed on ice in RIPA buffer. For immunoblottting of histones, the Episeeker
Histone Extraction Kit (Abcam, ab113476) was used to extract histones from 5 ×
106 cells according to the manufacturer’s instructions. Protein concentrations were
determined by Bradford assay (Bio-Rad, 5000006) and 40 μg of total protein was
analyzed by immunoblot. A Li-COR Odyssey system (Li-COR Biosciences) was
used for ﬂuorescent immunoblotting and quantiﬁcation was performed using
associated software. Uncropped images of immunoblots are presented in Supple-
mentary Fig. 11. The following primary antibodies were used for immunoblotting
at the indicated dilutions: H3K27me3 (C36B11) - Cell Signaling, 9733, 1/1000;
Ezh2 (D2C9) XP - Cell Signaling, 5246, 1/1000; ErbB2/c-Neu (AB3) - Calbiochem,
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OP15, 1/500; P-Rps6 Ser 240/244 - Cell Signaling, 5364, 1/1000; P-AMPK Thr172 -
Cell Signaling, 2535, 1/500; P-ACC Ser79 - Cell Signaling, 3661, 1/500; P-Src
Family Kinase Tyr416 - Cell Signaling, 2101, 1/500; α-Tubulin - Cell Signaling,
2144, 1/2000; β-Actin: Sigma-Aldrich, A5316, 1/2500; c-Src (clone GD11) - Mil-
lipore, 05-184, 1/1000; 4E-BP1 - Cell Signaling, 9644, 1/1000; P-4E-BP1 Ser65 -
Cell Signaling, 9451, 1/500; Rps6 - Cell Signaling, 2317, 1/1000; GAPDH - Novus,
NB300-322, 1/2000; Suz12 - Cell Signaling, 3737, 1/1000; EED - Millipore, 05-1320,
1/500; RbAp46 - Cell Signaling, 6882; RbAp48 - Abcam, ab79416; AMPKα - Cell
Signaling, 5832; ACC - Cell Signaling, 3676, 1/1000; Lkb1 - Cell Signaling, 3050, 1/
1000; α-Tubulin - Cell Signaling, 2125, 1/2000; Raptor - Cell Signaling, 2280, 1/500;
P-Raptor Ser792 - Cell Signaling, 2083, 1/250; Histone H3 - Cell Signaling, 14269,
1/1000; TSC2 - Cell Signaling, 4308, 1/1000; P-TSC2 Thr1462 - Cell Signaling,
3617, 1/500; P-TSC2 Ser1387 - Cell Signaling, 5584, 1/500; P-ErbB2 Tyr1221/1222
- Cell Signaling, 2243, 1/500; P-ErbB2 Tyr877 - Cell Signaling, 2241, 1/500; P-
ErbB2 Tyr1248 - Cell Signaling, 2247, 1/500; EGFR - Cell Signaling, 2232, 1/1000;
P-EGFR Tyr1068 - Cell Signaling, 3777, 1/500; ErbB3: Cell Signaling, 12708, 1/500;
P-ErbB3 Tyr1289 - Cell Signaling, 4791, 1/500; Akt - Cell Signaling, 2920, 1/1000;
P-Akt Ser473 - Cell Signaling, 4060, 1/1000; ERK1/2 - Cell Signaling, 9102, 1/1000;
P-ERK1/2 Thr202/Tyr204 - Cell Signaling, 9101, 1/1000; Puromycin - Millipore,
MABE343, 1/1000; eIF2α - Cell Signaling, 2103S, 1/1000; P-eIF2α Ser51 - Cell
Signaling, 3398S, 1/1000; mTOR - Cell Signaling, 2983, 1/1000; P-mTOR Ser 2448 -
Cell Signaling, 5536, 1/1000; PRAS40 - Millipore, 05-1070, 1/1000; P-PRAS40
Thr246 - Cell Signaling, 2997, 1/1000; mLST8 - Cell Signaling, 3274, 1/1000.
Secondary antibodies used in immunoblotting at a dilution of 1/10 000 were IRDye
800CW Donkey anti-rabbit (LI-COR Biosciences, 925-32213) and IRDye 680CW
Donkey anti-mouse (LI-COR Biosciences, 926-68072).
Immunoprecipitation. Cells were lysed in ice-cold RIPA buffer and lysated cleared
by centrifugation at 4 °C, 15,000 × g for 10 min. Protein concentrations were
determined by Bradford assay and Ezh2 was immunoprecipitated overnight at 4 °C
with end-over-end mixing from 500 µg of total cellular protein using 5 µl of
antibody (Ezh2 (D2C9) XP - Cell Signaling, 5246). Immunoprecipitates were
incubated with PureProteome protein A/G magnetic beads (Millipore, LSKMA-
GAG10) for 1 h and then washed ﬁve times in lysis buffer before analysis by SDS
PAGE and immunoblotting. Normal rabbit IgG (Cell Signaling, 2729) was used as
a negative control antibody for immunoprecipitations.
Puromycin incorporation assay. For puromycin incorporation assays24, cells were
treated with puromycin (10 µg/ml) for 15 min, lysed and processed for immuno-
blotting or immunoprecipitation as described above, with the exception that, for
immunoblotting, the Revert total protein stain (Li-COR Biosciences, 926-11010)
was used to quantify the total amount of protein present in each lane of the gel (Li-
COR Odyssey system, Li-COR Biosiences) prior to blocking and primary antibody
incubation (Millipore, MABE343, 1/1000) to detect puromycin incorporation.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction. Total RNA
was extracted from ﬂash frozen mammary tumors using an RNeasy Mini Kit
(Qiagen, 74106). cDNA was prepared by reverse transcribing the isolated RNA
using M-Mulv Reverse Transcriptase, Oligo-dT(23VN) and murine RNase inhi-
bitor (ProtoScript First Strand cDNA Synthesis Kit, New England Biolabs, E6300).
Real-time quantitative PCR was performed using LightCycler 480 SYBR Green I
MasterMix (Roche, 04887352001) and LightCycler 480 instrument (Roche) and
analyzed using associated software.
Microarray data acquisition and analysis. Affymetrix GeneChip Mouse Gene
2.0 ST arrays were used to analyze gene expression in c-Src-deﬁcient and control
mammary tumors. Total RNA was extracted from 4 NIC/c-Src+/+ and 4
NIC/c-SrcL/L tumors at tumor burden endpoint using the RNeasy Mini Kit and
quantiﬁed using a NanoDrop Spectrophotometer ND-1000 (NanoDrop Technol-
ogies, Inc.) RNA integrity was assessed using a Bioanalyzer 2100 (Aglient Tech-
nologies). Sense-strand cDNA was synthesized from 100 ng of total RNA and
fragmentation and labeling were performed to produce ssDNA with the GeneChip
WT Terminal Labeling Kit according to manufacturer’s instructions. After frag-
mentation and labeling, 3.5 µg DNA was hybridized on GeneChip Mouse Gene 2.0
ST arrays and incubated at 450C in the Genechip Hybridization oven 640 for 17 h
at 60 rpm. GeneChips were then washed in a GeneChips Fluidics Station 450 using
Hybridization Wash and Stain kit according to the manufacturer’s instructions and
scanned on a GeneChip scanner 3000. All procedures were performed at the
Genome Quebec Innovation Center, McGill University using arrays, kits and
apparatus from Affymetrix. Raw data were ﬁrst processed to perform gene-level
normalization and quality control using Affymetrix Expression Console software.
Gene Level Differential Expression Analysis of processed data was performed using
Affymetrix Transcriptome Analysis Console software. Differentially expressed
genes with ANOVA p-value <0.02 were considered in further analyses. A heatmap
of the ﬁltered gene expression dataset was generated using the Hierarchical Clus-
tering module in GenePattern software.
ChIP Enrichment Analysis (ChEA), interrogation of the ENCODE database,
KEGG and GO analyses were performed using the EnrichR online tool (http://amp.
pharm.mssm.edu/Enrichr/)69. Further analysis of gene regulation and pathways
was performed using Ingenuity Pathway Analysis (IPA - Qiagen) according to the
manufacturer's instructions.
For analysis of EZH2 mRNA translational efﬁciency in MCF7 cells, published
microarray data from total cellular mRNA and polysome-associated mRNA27 were
used. These data are available in the GEO database under accession number
GSE36847. The effects of metformin, PP242 and rapamycin on mRNA translation
were determined using analysis of partial variance (APV) and applied RVM with
treatment contrasts, as implemented in the anota R package70.
RNA-Seq. RNA was isolated from two independent NIC/c-Src+/+ and two NIC/c-
SrcL/L cell lines, each in biological duplicate, using an RNEasy mini kit (Qiagen,
74106) according to the manufacturer’s instructions. RNA concentration was
measured using a Qubit® 2.0 Fluorometer (Life Technologies, CA, USA) according
to the manufacturer’s instructions. Degradation and contamination were initially
assessed on 1% agarose gels and purity was determined using the NanoPhot-
ometer® spectrophotometer (IMPLEN). RNA integrity was then assessed using the
Bioanalyzer 2100 system (Agilent). In total 3 μg of RNA per sample was used to
generate sequencing libraries using the NEBNext® Ultra™ RNA Library Prep Kit for
Illumina® (New England Biolabs), following the manufacturer’s recommendations,
and index codes were added to attribute sequences to each sample. Brieﬂy, mRNA
was puriﬁed from total RNA using poly-T oligo-attached magnetic beads. Frag-
mentation was carried out using divalent cations under elevated temperature in
NEBNext First Strand Synthesis Reaction Buffer. First strand cDNA was synthe-
sized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase
H-). Second strand cDNA synthesis was subsequently performed using DNA
Polymerase I and RNase H. Remaining overhangs were converted into blunt ends
via exonuclease/polymerase activities. After adenylation of 3′ ends, NEBNext
Adapters with hairpin loop structure were ligated to prepare for hybridization. In
order to select cDNA fragments of preferentially 150–200 bp in length, the library
fragments were puriﬁed with AMPure XP system (Beckman Coulter). Then 3 μl
USER Enzyme (NEB) was used with size-selected, adapter-ligated cDNA at 37 °C
for 15 min followed by 5 min at 95 °C before PCR was performed with Phusion
High-Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer.
PCR products were puriﬁed (AMPure XP system) and library quality was assessed
on the Agilent Bioanalyzer 2100 system. Clustering of the index-coded samples was
performed on a cBot Cluster Generation System using the HiSeq PE Cluster Kit
cBot-HS (Illumina) according to the manufacturer’s instructions. The library
preparations were then sequenced on an Illumina Hiseq platform and 125 bp/150
bp paired-end reads were generated. Raw data (raw reads) in fastq format were
processed through in-house perl scripts to remove reads containing adapter or
poly-N and low quality reads from raw data. At the same time, Q20, Q30, and GC
content the clean data were calculated. Cleaned data were mapped to the genome of
the mouse strain FVB/N. An index of the reference genome was built using Bowtie
v2.2.3 and paired-end clean reads were aligned to the reference genome using
TopHat v2.0.12. HTSeq v0.6.1 was used to count the reads numbers mapped to
each gene, with FPKM of each gene calculated based gene length and read counts
(FPKM - expected number of Fragments Per Kilobase of transcript sequence per
Million base pairs sequenced) were calculated to estimate gene expression levels.
Differential expression analysis was performed using the DESeqR package (1.18.0)
and the resulting P-values were adjusted using Benjamini and Hochberg’s approach
for controlling the false discovery rate. Genes with an adjusted P-value < 0.05 found
by DESeq were assigned as differentially expressed. Analysis of transcriptional
regulation and pathway representation in differentially expressed genes from RNA-
Seq was performed using EnrichR and IPA as described above.
ChIP-Seq. ChIP-Seq to identify and quantify H3K27me3-bound genomic regions
was performed using a Drosophila melanogaster chromatin spike-in strategy71. In
total 5 μg of anti-H3K27me3 antibody (H3K27me3 (C36B11) - Cell Signaling,
9733) was immobilized overnight at 4 °C on 20 μl of Magna ChIP Protein A+G
magnetic beads (Millipore, 16-663) diluted in 250 μL of PBS+ 0.5% BSA and then
washed 3 times with PBS+ 0.5% BSA. MMTV-NIC cells in 15 cm plates were ﬁxed
with a 1% ﬁnal concentration of formaldehyde for 5 min at room temperature and
then lysed and sonicated. Equal amounts of chromatin from 2 individual cell lines
of each genotype were diluted in 2.5X ChIP dilution buffer (EDTA 2mM, NaCl
100 mM, Tris 20 mM, Triton 0.5%) + 100 μL of PBS+ 0.5% BSA and 750 ng of D.
melanogaster chromatin (Active Motif, 53083) and 0.4 µg of a D. melanogaster
H2Av-speciﬁc antibody (Active Motif, 39715) were added to each sample. Samples
were then added to the antibody-bound beads and left to rotate overnight at 4 °C.
Next, beads were washed 3 times for 3 min at 4 °C with 1 mL LiCl buffer (Tris 100
mM, LiCl 500 mM, Na-deoxycholate 1%) then once with 1 mL TE buffer. DNA was
eluted with 150 μL of elution buffer (0.1M NaHCO3, 0.1% SDS) overnight at 65 °C.
Chromatin immunoprecipitated DNA was puriﬁed using a QIAquick PCR pur-
iﬁcation kit (Qiagen, 28106) and eluted in 35 μL of elution buffer. Puriﬁed DNA
was sequenced using AAA base pair single end sequencing and reported as.fastq
ﬁles. Data was assayed for quality using FASTQC and processed using trimmo-
matic. D. melanogaster and mouse sequences were aligned to the BDGP6 and
mm10 reference genomes, respectively, using BWA. D. melanogaster sequence data
were then used to normalize mouse sequence data to remove background noise
from random reads71. PCR bias and other artifacts were removed by using
SAMtools and PICARDtools with default parameters and broad peaks were called
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through the use of MACS2 and HOMER with default parameters. Data were
visualized by creating tag density maps using the Galaxy ComputeMatrix pipeline.
Cell proliferation assays. CellTiter Aqueous MTS (Promega, G3580) (Fig. 9a) and
CyQuant (Invitrogen, C7026) (Supplementary Figs. 1e and 10d) proliferation
assays were performed in accordance with the manufacturer’s instructions. For
each time point, 5000 cells per well were seeded in quadruplicate in 96-well optical-
bottom plates (Nunc).
Polysome fractionation and analysis. NIC cells were cultured in 15 cm dishes,
washed twice with cold PBS containing 100 μg/ml cycloheximide (Sigma, C7698),
then scraped into PBS with 100 μg/ml cycloheximide, collected, and lysed in 450 μl
of hypotonic buffer (5 mM Tris–HCl [pH 7.5], 2.5 mM MgCl2, 1.5 mM KCl, 100
μg/ml cycloheximide, 2 mM DTT, 0.5% Triton X-100, and 0.5% sodium deox-
ycholate). Lysates were loaded onto 10–50% (wt/vol) sucrose density gradients (20
mM HEPES-KOH [pH 7.6], 100 mM KCl, and 5 mM MgCl2) and centrifuged at
36,000 rpm (SW 40 Ti rotor, Beckman Coulter, Inc.) for 2 h at 4 °C. Fractionation
of gradients with continuous recording of optical density at 254 nm was performed
using an ISCO fractionator (Teledyne ISCO). RNA was isolated from each fraction
and from total lysate (input) using TRIzol (Invitrogen, 15596018) according to the
manufacturer’s instructions, processed using an RNEasy MinElute cleanup kit
(Qiagen, 74204) according to the manufacturer’s instructions, and then analyzed by
QRT-PCR as described above.
Liquid Chromatography/Mass Spectrometry (LC/MS) Analysis. Cells were
washed three times in ice-cold 150 mM ammonium formate and metabolites were
extracted in 50% acetonitrile, 25% methanol, 25% water40. Targeted metabolite
analysis was performed on an Agilent 6430 triple quadrupole mass spectrometer
equipped with a 1290 Inﬁnity UPLC system (Agilent). Sample temperature was
maintained at 4 °C while solvents and column temperatures were maintained at 10
°C. Metabolites were separated using a 4.0 μm, 2.1 × 100.0 mm Cogent Diamond
Hydride column (MicroSolv Technology) operating at a ﬂow rate of 0.4 ml/min
and 5 μl sample injections. Separation solvent A consisted of 15 mM ammonium
formate in H2O, pH 5.8 and solvent B consisted of 15 mM ammonium formate in
85% acetonitrile in 15% H2O, pH 5.8. Chromatography started with a 2 min hold at
97% B, followed by a 5 min gradient to 70% B, then washed for 3 min with 98% A,
and re-equilibrated to starting conditions for 6 min. Separated metabolites were
introduced to the mass spectrometer via electrospray ionization (ESI) operating in
either positive or negative ionization mode and were analyzed by previously
optimized multiple reaction monitoring (MRM). Quantiﬁcation was accomplished
by comparing MRM peak areas to those from standard calibration curves using
MassHunter Quantitive Analysis software (Agilent). MRM transitions in negative
ionization mode for quantifying and qualifying ions were 506.0→ 158.9 and 506.0
→ 78.9 for ATP, 426.0→ 134 and 426.0→ 79 for ADP, 346.0→ 97 and 346.0→
78.9 for AMP. Gas temperature and ﬂow were set at 350 °C and 10 L/min.
Nebulizer pressure was set at 50 psi and capillary voltage was+ 4000 V.
Gas Chromatography/Mass Spectrometry (GC/MS) Analysis. Cells were
washed three times in ice-cold normal saline solution and water-soluble metabo-
lites were extracted in 80% methanol40. Samples dried by vacuum centrifugation
overnight at 4 °C were resuspended in 30 μl methoxyamine hydrochloride (MOX)
in anhydrous pyridine and added to GC–MS autoinjector vials containing 70μl N-
(tert-butyldimethylsilyl)-N-methyltriﬂuoroacetamide (MTBSTFA) derivatization
reagent. The samples were incubated at 70 °C for 1 h, after which aliquots of 1 μl
were injected for analysis. GC-MS data were collected on an Agilent 5975 C series
GC/MSD system (Agilent Technologies) operating in election ionization mode (70
eV) for selected ion monitoring (SIM). The relative amount of each metabolite was
determined from the integral ratios of the metabolites to the internal standard and
normalized to the number of cells extracted using Agilent MassHunter software.
Mass isotopomer distribution was determined using a published custom
algorithm72.
Respirometry and extracellular acidifcation measurements. Oxygen con-
sumption and extracellular acidiﬁcation rates were measured using an XFe96
Extracellular Flux Analyzer (Seahorse Bioscience) using the manufacturer’s
established protocols. In brief, cells were plated overnight in Seahorse 96-well plates
at 1 × 104 per well in 80 μL of complete media. Cells were washed three times in
non-buffered DMEM containing 25 mM glucose and 2 mM glutamine and incu-
bated in this medium in a CO2-free incubator at 37 °C for 2 h to allow for tem-
perature and pH equilibration before loading into the XFe96 apparatus. In addition
to basal measurements, the Mito Stress Test assay (Seahorse Bioscience, 103015-
100) was performed according to manufacturer’s instructions. XFe assays consisted
of sequential mix (3 min), pause (3 min), and measurement (5 min) cycles, allowing
for determination of OCR/ECAR every 10 min. At the end of the assay media was
removed from the plate which was then frozen at −80 °C for 24 h. CyQuant dye
(Invitrogen, C7026) was then used according to the manufacturer’s instructions to
generate DNA content values for data normalization. Data were analyzed using
Wave software (Seahorse Bioscience).
Analysis of metabolite levels in conditioned media. Glucose and lactate levels in
conditioned media were measured using a Flux Bioanalyzer (NOVA Biomedical)
according to the manufacturer’s instructions. For each condition tested, 2 ml of
conditioned culture medium from 1 × 106 cells cultured in 6-well plates (Nunc) for
24 h was used. Detached cells and debris were removed by centrifuging media at
15,000 × g for 10 min, 4 °C prior to use.
Quantiﬁcation and statistical analysis. Information on group sizes and statistical
tests performed for each experiment are in the ﬁgure legends. In general, unpaired
two-tailed Student’s t-tests were performed in GraphPad Prism or Microsoft Excel
software unless otherwise speciﬁed. One-way ANOVA with Tukey’s or Dunnett’s
post-hoc test for multiple comparisons and Kaplan-Meier analysis with logrank
tests (Mantel–Haenszel) were performed using GraphPad Prism. Spearman’s rank
correlation test for analysis of TMA data was performed using Statview (Abacus
Systems). Throughout the study, p < 0.05 was deﬁned as the threshold for
signiﬁcance.
Data availability
Gene expression and ChIP-Seq data generated in this study have been deposited in the
Gene Expression Omnibus (GEO) database as a SuperSeries with accession number
GSE130739 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130739].
Individual sub-series have the accession numbers GSE93892 (microarray data) [https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93892], GSE130661 (RNA-Seq data)
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130661] and GSE130738
(ChIP-Seq data) [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130738].
Published microarray data from total cellular mRNA and polysome-associated mRNA27
are available in the GEO database under accession number [https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE36847]. All other data from this study are available
within the Article and Supplementary Information or from the corresponding author
(WJM) upon request.
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